Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Transmission and prevention news

Show

From To
Blood scandal victims condemn Penrose inquiry

Victims of the contaminated blood scandal have reacted angrily to the findings of a long-awaited inquiry, branding the report a “waste of time and money”.

Published
26 March 2015
From
Scotsman
Penrose Inquiry: The key questions over contaminated blood

The findings of the Penrose Inquiry into the contamination of blood supplies in the 1970s and 80s have been published. Thousands of people were infected with Hepatitis C and HIV through blood transfusions and blood products.

Published
26 March 2015
From
BBC
More people in the UK are starting HIV treatment early, in order to reduce their risk of transmission

There is evidence of increasing interest in HIV treatment as prevention among people living with HIV in the UK, with the number of people starting treatment at

Published
25 March 2015
By
Roger Pebody
Good mental health associated with excellent adherence among people taking ART for prevention

Good mental health was the only significant factor associated with optimal pill-taking among people taking antiretroviral therapy (ART) for the prevention of sexual transmission of HIV,

Published
23 March 2015
By
Michael Carter
Canada: PrEP use now could save considerable sums in the future

A Canadian paper that weighs the cost of using pre-exposure prophylaxis (PrEP) to prevent HIV infections against the lifetime total cost of one HIV infection finds that,

Published
20 March 2015
By
Gus Cairns
Vatican adopts HIV/AIDS treatment model developed in BC

Dr. Montaner said he had a “brief and very pleasant” meeting with the Pope during a “greeting line” at the Vatican on March 11. He also spent several hours with the Catholic church’s equivalent of a minister of health and a minister of justice, who plan to use his method, called treatment as prevention (TasP), in a pilot program that could involve 140,000 patients in Tanzania.

Published
20 March 2015
From
The Globe and Mail
The State of HIV/AIDS Science and Treatment Literacy in the HIV/AIDS Workforce

This survey yields some disturbing findings. Overall, the HIV science and treatment knowledge of the HIV/AIDS workforce is far too low. In many cases, people working in HIV/AIDS appear to doubt the science behind breakthrough biomedical tools for HIV prevention, and far too many members of the workforce are not familiar with many of the bio-medical interventions that will play a critical role in ending the epidemic.

Published
18 March 2015
From
Black AIDS Institute
US: A Near-Failing Science Grade for the Non-Medical HIV Workforce

On average, the survey respondents answered just 63 percent of the questions correctly, including 76 percent of those covering basic knowledge and terminology, 56 percent of the HIV treatment questions, and 46 percent of those on the use of ARVs to prevent transmission of the virus. Only 19 percent of the respondents scored 80 percent or higher on the test.

Published
18 March 2015
From
AIDSMeds
New Model Finds HIV Acute-Phase Infectivity May be Lower Than Previously thought

Previous calculations may have overestimated the importance of HIV transmission from recently infected individuals ("acute-phase infectivity") in driving HIV epidemics, according to an article published by Steve Bellan of the University of Texas at Austin and colleagues in this week's PLOS Medicine. The lower estimates of acute phase infectivity suggest that recently infected individuals--who have not had the chance to start antiretroviral treatment--although still more infectious on average than those in the chronic stage of infection, are not as likely to infect others as was previously thought.

Published
18 March 2015
From
Infection Control Today
When Might Generic Truvada Be Available for PrEP in the US?

Our best guess is that generic Truvada could be available in December 2017, initially produced by Teva, a major generic producer. Two other generic companies, Lupin Pharmaceuticals and Cipla may follow soon after creating competition that can really bring prices down.

Published
17 March 2015
From
Ethan The Blog

Filter by country